Archimica S.p.A.

Archimica S.p.A. is an Italian manufacturer of active pharmaceutical ingredients (APIs) and GMP building blocks, headquartered in Lodi Vecchio, Italy. The company operates a chemical manufacturing and process-development site that traces its industrial lineage back to 1947, when Istituto Chemioterapico Italiano (I.C.I.) was founded. Over subsequent decades the Lodi site passed through several corporate owners and identities, including Prime European Therapeuticals S.p.A. (Euticals), Mandarin Capital Partners, Clessidra, AMRI and Livia, before being branded Archimica S.p.A. in 2019. In 2023 Archimica was acquired by PI Health Sciences, under which it continues to operate. Archimica positions itself as a specialist in difficult-to-handle chemical technologies, offering process development and manufacturing from clinical scale through to large commercial scale for both innovative and generic pharmaceutical companies. Its stated strengths include experience with challenging reagents, reactions and substance classes, agile capacity availability, flexible manufacturing and development, European manufacturing, and premium client attention. The company describes 77 years of continuity of supply into the world pharmaceutical market, counting from the 1947 foundation of its predecessor. Archimica's product offering centres on APIs, GMP building blocks and reagents. Its commercial generic API portfolio includes Cytarabine (a nucleoside analogue), Hydroxyurea (a modified urea), Mianserin (a tetracyclic), Sucralfate (saccharose sulfate), Sulfathiazole (a sulfonamide), and Sucrose octasulfate potassium salt (KSOS, non-API grade), alongside Glycerophosphoryl-Choline. Several of these products are covered by CEPs (Certificates of Suitability). The company states that it serves all therapeutic classes and all substance classes, including anticancer APIs. According to its own company profile, Archimica has 7 active products, 24 active Drug Master Files across 39 countries, 200 active customers and supplies 50 countries worldwide. Its customers rely on Archimica's products and services for quality medicines globally. The company operates as a contract development and manufacturing organisation (CDMO) and API supplier, with its manufacturing base in Europe and a customer footprint extending internationally.

Archimica's history is rooted in the Lodi chemical and pharmaceutical manufacturing site in Italy, which the company describes as having 77 years of continuity of supply into the world pharmaceutical market. The lineage begins in 1947 with the foundation of Istituto Chemioterapico Italiano (I.C.I.). That entity established the industrial and pharmaceutical chemical capabilities that would later be carried forward at the Lodi site. In 1984, Prime European Therapeuticals S.p.A. (Euticals) was founded, becoming the next major identity associated with the site. Euticals developed as a producer of APIs and pharmaceutical intermediates. In 2008, Mandarin Capital Partners became the majority shareholder of Euticals, marking a period of private-equity ownership. In 2012, Clessidra, an Italian financial fund, became the majority shareholder of Euticals, continuing the pattern of financial-investor control. In 2016, AMRI acquired the Euticals Group, bringing the Lodi operations into a larger international contract research and manufacturing organisation. That ownership phase was relatively short. Effective 1 August 2019, Livia acquired the Lodi site and branded it Archimica S.p.A., giving the business its current name and a renewed standalone identity. Under the Archimica brand, the company continued to supply APIs, GMP building blocks and reagents to pharmaceutical customers. In 2023, PI Health Sciences acquired Archimica S.p.A., making Archimica part of the PI Health Sciences group. The company continues to operate from Lodi Vecchio, Italy, and presents itself as a European-based manufacturer with global reach. Its own company profile reports 7 active products, 24 active Drug Master Files in 39 countries, 200 active customers and supply to 50 countries worldwide, reflecting a long-established export-oriented API business.

• 2023

  PI Health Sciences acquires Archimica S.p.A.

• 2019

  Effective August 1, Livia acquires the Lodi site and brands it Archimica S.p.A.

• 2016

  AMRI acquires the Euticals Group.

• 2012

  Clessidra, an Italian financial fund, becomes majority shareholder of Euticals.

• 2008

  Mandarin Capital Partners becomes majority shareholder of Euticals.

• 1984

  Foundation of Prime European Therapeuticals S.p.A. (Euticals).

• 1947

  Foundation of Istituto Chemioterapico Italiano (I.C.I.), the origin of the Lodi site's pharmaceutical chemical operations.

Specialist CDMO and API supplier focused on difficult-to-handle chemical technologies, European manufacturing, and flexible development and commercial-scale production for innovative and generic pharmaceutical customers.

• Cytarabine (nucleoside analogue) – CEP

• Hydroxyurea (modified urea) – CEP

• Mianserin (tetracyclic) – CEP

• Sucralfate (saccharose sulfate)

• Sulfathiazole (sulfonamide)

• Sucrose octasulfate potassium salt (KSOS) – non-API grade

• Glycerophosphoryl-Choline

• GMP building blocks

• Reagents

1. 1Archimica S.p.A. | Active Pharmaceutical Ingredients & Intermediatesarchimica.com
2. 2Archimica - Wikidatawikidata.org